Business Context and Reporting Period
Company: Innate Pharma S.A.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date of Report: April 24, 2025
Principal Executive Office: Marseille, France
Context: This filing incorporates by reference a press release (Exhibit 99.1) dated April 24, 2025, into the company's registration statements on Form F-3 and Form S-8. The document serves as a formal notification of the press release content to the SEC.
Key Financial Metrics
The provided filing text does not contain specific financial data. It is a cover document referencing an external press release. Consequently, the following metrics are not available in this text:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt Levels
- Liquidity Position
Material Changes
The filing text does not provide details on material changes versus prior periods. The specific nature of the update is contained within the referenced Exhibit 99.1 (Press Release), which is not included in the input text.
Guidance, Outlook, and Risks
Management Commentary: The filing notes the inclusion of a press release but explicitly excludes a quotation from Jonathan Dickinson, Chairman of the Executive Board and CEO, from the incorporation by reference.
Guidance and Risks: No specific guidance, outlook, risk factors, contingencies, or unusual items are detailed in the provided text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated April 24, 2025) to understand the specific corporate event or announcement triggering this filing.
- Verify the content of the press release for any updates on clinical trial progress, regulatory approvals, or partnership agreements, as these are typical drivers for Innate Pharma 6-K filings.
- Check the referenced registration statements (Form F-3 File No. 333-276164 and Form S-8 File No. 333-282031) to see how this new information impacts the company's capital raising capabilities.
- Confirm if the excluded CEO quotation contains material information not present in the rest of the press release.